STERLING WINTHROP PHARMACEUTICALS PRESIDENT IS JACQUES REJEANGE

STERLING WINTHROP PHARMACEUTICALS PRESIDENT IS JACQUES REJEANGE, who moves from Sandoz to fill the newly-created position with worldwide responsibility for Sterling's pharmaceutical business. Rejeange, who also will hold the title of corporate exec VP, worked for Sandoz for 26 years, serving as president and CEO of Sandoz U.S. since 1989. Rejeange worked at Pfizer before moving to Sandoz, where he held a number of international positions in Switzerland, Hong Kong, U.K., France and Belgium. A native of France, Rejeange was the Sandoz representative to the board of directors of the Pharmaceutical Manufacturers Association. With Sanofi as a major partner in Sterling Winthrop, Rejeange's European background should be helpful in the melding of the French and U.S. merged operations. Commenting on the appointment, Sterling Winthrop Chairman Louis Mattis said: "Jacques will be instrumental in translating Sterling Winthrop's strategic framework management process into focused, global actions for success." Mattis has been serving as acting president of the pharmaceuticals operation since October 1991, when the Sterling Winthrop organizational structure combining the Kodak and Sanofi drug and consumer product marketing operations was unveiled. Sanofi Winthrop Pharmaceuticals USA President Harry Shoff and International President Jacques Boisvert have reported directly to Mattis during that period. Rejeange's departure from Sandoz continues a management drain from the Swiss firm's U.S. operations. Rejeange ascended to the top Sandoz Pharmaceuticals position in the U.S. after Fred Hassan departed to head Wyeth-Ayerst. In October 1989, Robert Essner also moved to Wyeth-Ayerst as Exec VP, followed by Robert Levy, president of Sandoz research, who joined the American Home Products pharmaceutical subsidiary in March of this year. Manfred Karobath, a senior VP of R&D recently moved to Rhone-Poulenc Rorer. No successor to Rejeange has been announced. The management shuffle at Sandoz may complicate the company's efforts to increase its reach and presence in the U.S. market. The firm has been very active in start-up investments and collaborative deals and Swiss execs made a first effort at establishing relations with the U.S. securities analysts in a New York presentation last November.